← FDA DRUG APPROVALS

FDA ANDA · ANDA214138

EVEROLIMUS

Sponsor: ALKEM LABS LTD

APPLICATION
ANDA214138
TYPE
ANDA
ORIGINAL APPROVAL
2021-11-26
LATEST ACTION
2024-10-04
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

EVEROLIMUSPrescription
EVEROLIMUS 1MG · TABLET · ORAL
EVEROLIMUSPrescription
EVEROLIMUS 0.5MG · TABLET · ORAL
EVEROLIMUSPrescription
EVEROLIMUS 0.75MG · TABLET · ORAL
EVEROLIMUSPrescription
EVEROLIMUS 0.25MG · TABLET · ORAL

Approval history

2024-10-04Labeling · Supplement 9 · standardAP
2024-10-04Labeling · Supplement 8 · standardAP
2021-11-26UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →